Pharmacia resolves warning letter issues
Executive Summary
FDA is satisfied with Pharmacia's response to its April 17 warning letter relating to Caguas, Puerto Rico plant, company says (1"The Pink Sheet" May 20, p.7)...
You may also be interested in...
Pharmacia Is “Recidivist” On GMPs, FDA Says After Two Warnings In 5 Years
FDA considers two GMP warning letters issued to the same plant more than five years apart to be evidence that a company is "recidivist" on compliance issues, the agency told Pharmacia
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.